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ORAL PRESENTATION 8:
Mutation in PIK3CA leading to developmental mosaic disorders
Yeung KS,1 Leung GKC,1 Wong WL,1 Li CH,2 Choi KY,3 Kuong E,4 Chow W,4 To M,4
Ip J,5 Chow CP,6 Chan GCF,1 Chung BHY1
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Background and aims
Mutation in phosphatidylinositol-4, 5-bisphosphate 3-kinase (PIK3CA), one of the genes
involved in the PI3K/AKT/mTOR pathway, is associated with developmental mosaic
disorders which are now collectively termed as PIK3CA-Related Overgrowth Spectrum
(PROS). PROS can be further divided into two subgroups based on the affected body
systems, which are body asymmetrical overgrowth and central nervous system (CNS)
overgrowth respectively. Body asymmetrical overgrowth includes diseases such as
CLOVES Syndrome, Klippel-Trenaunay Syndrome, Cystic Hygroma and Fibroadipose
Hyperplasia. More than 90% of these patients have somatic mutations in one of the 4
mutation hotspots in PIK3CA. CNS overgrowth includes diseases such as Megalencephaly
Polymicrogyria Polydactyly Hydrocephalus Syndrome (MPPH) and Megalencephaly
Capillary Malformation Syndromes (MCAP). Patients who have CNS overgrowth have
megalencephaly and at the same time developmental delay and/or autistic spectrum
disorder. We have ten patients that are suspected to have PROS, and we aim to identify
the diseasing causing mutation in each patient.
Methods
For patients who have body asymmetrical overgrowth, somatic mutations can only be
detected on affected tissues. Since there are mutation hotspots, digital PCR was used to
identify low level somatic mosaicism. For the 2 patients with CNS overgrowth, mutation
can be detected on blood, saliva and buccal tissues. Whole exome sequencing was used
to identify the diseasing causing mutation.
Results
In 7 out of 8 patients with asymmetrical overgrowth, somatic mutations in PIK3CA have
been identified. The percentage of mutant in these patients ranged from 3.3% to 31.6%.
For the 2 remaining patients with CNS overgrowth, 1 reported somatic mutation with 4.5%
mutant and 1 novel germline mutation in PIK3CA have been identified.
Conclusion
In order to obtain a molecular diagnosis of PROS, the correct choices of affected tissues and
sequencing technology are important. Surgical debulking is now the only option for treatment
for PROS. With the identification of mutations in PIK3CA, inhibitors that inhibit PI3K/AKT/
mTOR pathway may be used in controlling the progressive overgrowth in patients.
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